Brokers Offer Predictions for CureVac FY2025 Earnings

CureVac (NASDAQ:CVAC) – Equities researchers at Leerink Partnrs upped their FY2025 earnings per share estimates for CureVac in a report released on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($0.54) per share for the year, up from their previous estimate of ($0.60). The consensus estimate for CureVac’s current full-year earnings is $0.72 per share.

CureVac Stock Down 2.8 %

CVAC opened at $3.85 on Friday. The stock’s 50 day moving average price is $3.34 and its 200 day moving average price is $3.20. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The stock has a market cap of $861.94 million, a P/E ratio of 7.00 and a beta of 2.50. CureVac has a 12 month low of $2.21 and a 12 month high of $5.28.

Hedge Funds Weigh In On CureVac

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp acquired a new stake in shares of CureVac in the 2nd quarter worth approximately $54,000. Vanguard Personalized Indexing Management LLC lifted its position in CureVac by 99.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company’s stock worth $147,000 after purchasing an additional 21,999 shares during the period. XTX Topco Ltd bought a new position in CureVac during the 2nd quarter valued at $108,000. Point72 Asset Management L.P. bought a new position in CureVac during the 2nd quarter valued at $8,237,000. Finally, Green Alpha Advisors LLC increased its position in shares of CureVac by 41.3% during the 3rd quarter. Green Alpha Advisors LLC now owns 27,319 shares of the company’s stock valued at $80,000 after purchasing an additional 7,979 shares during the period. Institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.